As expected, following a positive recommendation from its advisory panel in September, the European Medicines Agency has granted approval for Emgality (galcanezumab), in the treatment of migraines.
Eli Lilly (NYSE: LLY) says it has won approval to market the CGRP-inhibitor for the prophylaxis of migraine in adults who have at least four migraine days per month.
Emgality was approved in the USA in September, the third such migraine therapy to be approved, after Amgen’s (Nasdaq: AMGN) Aimovig (erenumab) and Teva Pharmaceutical’s (NYSE: TEVA) Ajovy (fremanezumab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze